{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:25:23Z","timestamp":1784870723784,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Danish Health Authority","award":["WP5.5"],"award-info":[{"award-number":["WP5.5"]}]},{"name":"NEYE Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Danish Comprehensive Cancer Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Department of Oncology, Herlev Gentofte Hospital","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Maersk Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-8TY"],"award-info":[{"award-number":["CA209-8TY"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"A grant from the radiotherapy research collaboration between Rigshospitalet and Herlev-Gentofte Hospital, Denmark via Varian Inc. Medical Systems, Siemens","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immunotherapy with checkpoint inhibitors (CPIs) has revolutionised cancer treatment but has no convincing effect in metastatic castration-resistant prostate cancer (mCRPC). It has been suggested that a combination of CPI and hypofractionated stereotactic body radiotherapy (SBRT) may work synergistically, and recent trials have supported this. We hypothesise that adding SBRT to CPI treatment can improve response rates in patients with mCRPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The CheckPRO trial is an open-label, randomised, two-stage, phase II trial. We aim to enrol and randomise 80 evaluable patients with mCRPC who progressed following \u22652 lines of treatment. Enrolment started in November 2019 with 38 months expected enrolment period. The participants receive treatment for 52 weeks including four cycles of ipilimumab and nivolumab with or without concomitant SBRT (24 Gray in three fractions) to a single soft tissue or bone metastasis, followed by 10 cycles of nivolumab. Participants are followed until progression, death, or for 12 months after the end of treatment.<\/jats:p><jats:p>Co-primary endpoints are the objective response rate and prostate-specific antigen (PSA) response rate. Secondary endpoints include safety, radiographic progression-free survival, clinical benefit rate, duration of response, PSA-progression-free survival beyond 12 weeks, quality of life and overall survival. Exploratory endpoints include translational analyses of tumour biopsies and consecutive blood samples. Biopsies from metastatic sites are collected at baseline, before the third treatment and at the end of treatment. Blood sampling for immune monitoring and circulating tumour DNA is performed consecutively at baseline and every radiographic assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study follows the Helsinki Declaration and is approved by the Danish Ethics Committee System (journal no. H-19016100). All participants must receive written and oral information and provide a signed informed consent document prior to inclusion. The study results will be published in an international peer-review journal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>EudraCT number: 2018-003461-34. clinicaltrials.gov ID<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05655715\">NCT05655715<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063500","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:59:04Z","timestamp":1675097944000},"page":"e063500","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Randomised phase II trial of stereotactic body radiotherapy in combination with<b>check<\/b>point inhibitors in metastatic castration-resistant<b>pro<\/b>state cancer (CheckPRO): a study protocol"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05655715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05655715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02601014","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04717154","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03061539","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-7701","authenticated-orcid":false,"given":"Nicklas Juel","family":"Spindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-3256","authenticated-orcid":false,"given":"Gitte Fredberg","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Lisbeth","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrid V","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Al-Farra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Westergren","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke L\u00f8vendahl","family":"Eefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"2023013008300673000_13.1.e063500.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2023013008300673000_13.1.e063500.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2023013008300673000_13.1.e063500.3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002919"},{"key":"2023013008300673000_13.1.e063500.4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"2023013008300673000_13.1.e063500.5","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"2023013008300673000_13.1.e063500.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1965"},{"key":"2023013008300673000_13.1.e063500.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"2023013008300673000_13.1.e063500.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102057","article-title":"Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes","volume":"88","author":"Claps","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2023013008300673000_13.1.e063500.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.02.014"},{"key":"2023013008300673000_13.1.e063500.10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.euo.2020.10.010","article-title":"A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy?","volume":"4","author":"Heidegger","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2023013008300673000_13.1.e063500.11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"2023013008300673000_13.1.e063500.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2023013008300673000_13.1.e063500.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2023013008300673000_13.1.e063500.14","unstructured":"WSME T , Chen D , Verma V . Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med."},{"key":"2023013008300673000_13.1.e063500.15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality","volume":"95","author":"Ko","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"2023013008300673000_13.1.e063500.16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2023013008300673000_13.1.e063500.17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in Postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"2023013008300673000_13.1.e063500.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0246-1"},{"key":"2023013008300673000_13.1.e063500.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023013008300673000_13.1.e063500.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2023013008300673000_13.1.e063500.21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"Uk consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol"},{"key":"2023013008300673000_13.1.e063500.22","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081"},{"key":"2023013008300673000_13.1.e063500.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2023013008300673000_13.1.e063500.24","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1002\/sim.5829","article-title":"Designs for randomized phase II clinical trials with two treatment arms","volume":"32","author":"Hou","year":"2013","journal-title":"Stat Med"},{"key":"2023013008300673000_13.1.e063500.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.024"},{"key":"2023013008300673000_13.1.e063500.26","doi-asserted-by":"publisher","DOI":"10.2307\/2281868"},{"key":"2023013008300673000_13.1.e063500.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2293"},{"key":"2023013008300673000_13.1.e063500.28","unstructured":"Kwan EM , Spain L , Anton A . Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur Urol."},{"key":"2023013008300673000_13.1.e063500.29","doi-asserted-by":"crossref","unstructured":"Boudadi K , Suzman DL , Luber B , et al . STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC). JCO 2016;34:TPS5089.doi:10.1200\/JCO.2016.34.15_suppl.TPS5089","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5089"},{"key":"2023013008300673000_13.1.e063500.30","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1016\/j.annonc.2021.08.1155","article-title":"642TiP phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer","volume":"32","author":"Mehra","year":"2021","journal-title":"Ann Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:59:49Z","timestamp":1675097989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,30]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bmjopen-2022-063500"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063500","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}